Vaccines Advisory Committee Splits on Safety, Effectiveness of Sanofi’s Dengvaxia

Drug Industry Daily
A A
An FDA advisory committee voted narrowly on Thursday against the effectiveness of Sanofi’s dengue virus vaccine and split evenly on its safety, except for children aged nine to 16.

To View This Article:

Login

Subscribe To Drug Industry Daily